The COVID-19 pandemic is still a big global threat, with high death already reported in many nations. Despite the critical need for a proven therapy option, the treatment choices for COVID-19 remain unknown. The SARS-CoV-2 virus has been tested with a variety of repurposed drugs. Ivermectin, an antiparasitic with antiviral and anti-inflammatory effects, has also been used to treat moderate COVID-19 infections. Its use has been approved by many national and international guidelines. The cumulative evidence from subsequent clinical trials, on the other hand, has revealed no meaningful clinical advantages. Non-target species such as insects and other environmental matrices may be exposed to ecotoxicological consequences if a portion of the ivermectin administered is excreted unchanged in the faeces and ends up in the soil. Despite this, Ivermectin is often used and should be avoided because evidence from several clinical trials does not support its usage, and dose discrepancies may be to blame for the lack of solid clinical efficacy.
Author(s) Details:
Ajay Kumar Shukla,
AIIMS, Bhopal, India.
Saurav Misra,
KCGMC, Karnal, India.
Shubham Atal,
AIIMS, Bhopal, India.
No comments:
Post a Comment